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A high throughput ultra pressure liquid chromatography–mass spectrometry (UPLC–MS/MS) method
with good sensitivity and selectivity has been developed and validated for simultaneous quantiﬁcation of
esomeprazole, rabeprazole and levosulpiride in human plasma using lansoprazole as internal standard
(IS). The extraction method based on liquid–liquid extraction technique was used to extract the analytes
and IS from of 50 mL of human plasma using methyl tert-butyl ether:ethyl acetate (80:20, v/v), which
offers a high recovery. Chromatographic separation of analytes and IS was achieved on a Hypersil gold C18
column using gradient mobile phase consisting of 2 mM ammonium formate/acetonitrile. The ﬂow rate
was set at 0.5 mL/min to elute all the analytes and IS within 1.00 min runtime. Detection of target
compounds was performed on a triple quadruple mass spectrometer by multiple reaction monitoring
(MRM) mode via positive electrospray ionization (ESI). Method validation results demonstrated that the
developed method has good precision and accuracy over the concentration ranges of 0.1–2000 ng/mL for
each analyte. Stability of compounds was established in a battery of stability studies, i.e., bench top,
autosampler, dry extract and long-term storage stability as well as freeze-thaw cycles. The validated
method has been successfully applied to analyze human plasma samples for application in pharmaco-
kinetic studies.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Esomeprazole is chemically (S)-5-methoxy-2-[(4-methoxy-3,
5-dimethylpyridin-2-yl) methylsulﬁnyl]-3H-benzoimidazole (Fig. 1).
Esomeprazole (S-isomer of omeprazole), the ﬁrst single optical isomer
proton pump inhibitor, generally provides better acid control than
current racemic proton pump inhibitors and has a better pharmaco-
kinetic/pharmacodynamic proﬁle relative to racemic product ome-
prazole [1]. Esomeprazole is a potent inhibitor of gastric acid secretion
and accumulates in the acidic compartment of the parietal cells where
the molecule is transformed to its active sulfonamide form [2]. It has
been well proven as an effective agent in the treatment of gastro-
esophagitis reﬂux disease (GERD), functional dyspepsia, nonsteroidal
antiinﬂammatory drugs-induced gastric-intestinal symptoms, ulcers,
Helicobacter pylori infection and Zollinger-Ellison syndrome [3–6].
Rabeprazole is chemically 2-([4-(3-methoxypropoxy)-3-me-
thylpyridin-2-yl] methyl sulﬁnyl)-1H-benzo[d]imidazole (Fig. 1).on and hosting by Elsevier B.V. Th
University.
hunduri).Rabeprazole, a new proton pump inhibitor, belongs to a class of
substituted benzimidazole molecules [7]. Rabeprazole covalently
binds and inactivates the gastric parietal cell Hþ/Kþ-ATPase, the
proton pump responsible for the terminal step in gastric acid se-
cretion [8]. It is clinically effective in the treatment of acid related
diseases such as gastric ulcers, duodenal ulcers, GERD, functional
dyspepsia and peptic ulcer disease, in association with Helico-
bacter pylori eradication [9].
Levosulpiride is chemically N-[[(2S)-1-ethylpyrrolidin-2-yl]
methyl]-2-methoxy-5-sulfamoyl benzamide (Fig. 1). Levosulpiride
is a levo enantiomer of sulpiride and a benzamide derivative, in-
dicated as an antipsychotic, antidepressant, antiemetic and anti-
dyspeptic drug, as well as a drug for the treatment of somatoform
disorders [10]. Levosulpiride is an antidopaminergic gastro-
intestinal prokinetic agent and its effect is mediated through the
blockade of enteric (neuronal and muscular) inhibitory D2 re-
ceptors [11]. It has been shown to increase lower esophageal
sphincter pressure, accelerate gastric emptying, enhance gall-
bladder emptying, and improve symptoms in functional dyspepsia
and diabetic gastroparesis [12].
The combined usage of proton pump inhibitors (esomeprazole
and rabeprazole) and prokinetics (levosulpiride) shows moreis is an open access article under the CC BY-NC-ND license
Fig. 1. Chemical structures of esomeprazole, rabeprazole and levosulpiride.
Fig. 2. Product ion mass spectra of [MþH]þof (A) esomeprazole, (B) rabeprazole
and (C) levosulpiride.
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dyspepsia [13]. Delayed gastric emptying, Helicobacter pylori infec-
tion, abnormal duodenojejuanal motility, and central nervous system
dysfunction are major causes of functional dyspepsia; hence, these
patients are subjected to combination therapy with proton pump
inhibitors and prokinetics to get effective treatment [14]. So there is a
need for the method to estimate the plasma concentrations of
esomeprazole, rabeprazole and levosulpiride simultaneously.
As per literature, several liquid chromatography tandem mass
spectrometry (LC–MS/MS) methods are reported for the estima-
tion of esomeprazole [15–17], rabeprazole [18–22] and levo-
sulpiride [23–25] individually in biological samples. Till date, there
is no ultra pressure liquid chromatography–mass spectrometry
(UPLC–MS/MS) method available for the estimation of esome-
prazole, rabeprazole and levosulpiride simultaneously in human
plasma. The reported methods have major disadvantages includ-
ing lacked sensitivity and a longer runtime. The method proposed
by Gopinath et al. [17] for determination of esomeprazole in hu-
man plasma is sensitive but it has used expensive solid phaseextraction technique for sample preparation. Other methods re-
ported by Hultman et al. [15] for determination of esomeprazole in
human, rat and dog plasma and Mogili et al. [16] for quantiﬁcation
of esomeprazole in human plasma requires long chromatographic
run which is not useful for analyzing more samples per day. The
method developed by Hishinuma et al. [19] for the quantiﬁcation
of rabeprazole in human serum is sensitive with lower limit of
quantiﬁcation of 0.25 ng/mL, but the method needs long chro-
matographic run time. Another method reported by Huang et al.
[20] for the quantiﬁcation of rabeprazole in human plasma, has
utilizes very small amount of plasma for sample preparation, but
this method also requires longer chromatographic run time which
is not suitable for high throughput sample analysis. Phapale et al.
[23] reported the LC–MS/MS method for quantiﬁcation of levo-
sulpiride in human plasma, but it has long chromatographic run-
time compared to the current proposed UPLC method.
The present study describes a simple, selective and sensitive
method, which employs liquid–liquid extraction technique for
sample preparation and liquid chromatography with electrospray
ionization (ESI)–tandem mass spectrometry for simultaneous
quantitation of esomeprazole, rabeprazole and levosulpiride in
human plasma. The proposed method has signiﬁcant advantages
over earlier reported methods like simultaneous quantiﬁcation of
three analytes, shorter run time (1.00 min), wider linearity range
with a more sensitivity (lower limit of quantiﬁcation:0.1 ng/mL),
and simple reproducible extraction. The present method has been
validated as per the current US Food and Drug Administration
(USFDA) guidelines [26]. The application of this assay in a clinical
pharmacokinetic study following oral administration of esome-
prazole, rabeprazole and levosulpiride is described.2. Experimental
2.1. Materials and reagents
Reference standards of esomeprazole magnesium hydrate, ra-
beprazole sodium, levosulpiride and lansoprazole (internal stan-
dard, IS) were purchased from Sigma-Aldrich (Hyderabad, India).
HPLC grade ammonium formate was procured from Thermo Fisher
Scientiﬁc (Mumbai, India). HPLC grade methanol and acetonitrile
were procured from J.T Baker (Phillipsburg, USA). Milli-Q water
(18.2 mΩ and TOCr50 ppb) generated using a Milli-Q puriﬁca-
tion system (Millipore, Bangalore, India) was used throughout the
study. Methyl tert-butyl ether and ethyl acetate were purchased
from Rankem (Hyderabad, India). Drug-free human plasma was
procured from King George Hospital (Visakhapatnam, India).
2.2. Chromatographic and mass spectrometric conditions
Waters Acquity UPLC system (Waters corporation, Milford, USA),
consisting of binary solvent manager, sample manager and column
manger, was used for solvent and sample delivery. Mobile phase A
consisted of 2 mM ammonium formate in Milli-Q water and mobile
phase B was acetonitrile. The analytes and IS were separated by the
following gradient (minutes, % mobile phase B): 0.01, 10; 0.20, 10;
0.50, 90; 0.70, 90; 0.80, 10; 1.00, 10, and delivered with a ﬂow rate of
0.5 mL/min on a Hypersil Gold C18 column (50 mm3.0 mm,
1.9 mm; Thermo scientiﬁc, India) maintained at 40 °C. The sample
manager was maintained at 5 °C and injection volume was 2 mL. The
total chromatographic run time was 1.00 min. The analytes and IS
were detected using a Waters XEVO triple quadruple mass spec-
trometer (Waters corporation, Milford, USA) equipped with Z spray
source. The quantiﬁcations of the analytes and IS were achieved by
operating the mass spectrometer in positive ion ESI with multiple
reaction monitoring (MRM) mode. Nitrogen gas was used as both
Fig. 3. Typical multiple reaction monitoring mode chromatograms of analytes: (A) esomeprazole, (B) rabeprazole and (C) levosulpiride (left panel) in human blank plasma
and IS (right panel).
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13,333.33 mL/min, respectively. The source dependent parameters,
i.e., capillary voltage, extractor voltage, source temperature and
desolvation temperature, were set at 3.50 kV, 3 V, 150 °C and 500 °C,
respectively. The precursor to product ion transitions along with the
cone voltage and collision energy for each analyte and IS were as
follows: m/z 346.1-198.1, 21 V, 14 eV for esomeprazole; m/z
360.1-242.1, 20 V, 12 eV for rabeprazole; m/z 342.2-112.2, 15 V,
16 eV for levosulpiride; m/z 370.2-252.1, 20 V, 20 eV for IS with a
dwell time 100 ms. Data acquisition and calculations were per-
formed using Masslynx software, version 4.0.
2.3. Preparation of calibration standards and quality control samples
Individual standard stock solutions of esomeprazole, rabe-
prazole and levosulpiride were prepared by dissolving requisite
amounts in methanol to obtain the ﬁnal drug concentration of1 mg/mL, respectively. A series of combined working stock so-
lutions with concentrations in the range of 0.1–2000 ng/mL were
prepared by serial dilutions with methanol:water (70:30, v/v).
Calibration standards were prepared by spiking (2% of total
plasma volume) in blank human plasma with combined working
stock solutions. A nine-point calibration curve standards were
made at 0.1, 0.2, 1.0, 5.0, 50.0, 500.0, 1000.0, 1600.0 and
2000.0 ng/mL concentrations, respectively. The quality control
(QC) samples were similarly prepared at concentration of
1600 ng/mL (high quality control, HQC), 1000 ng/mL (middle
quality control, MQC), 1.0 ng/mL (low quality control, LQC) and
0.1 ng/mL (lower limit of quantiﬁcation quality control, LLOQ QC)
with blank human plasma by separate weighting of standards.
Stock solution (1 mg/mL) of IS was prepared by dissolving ap-
propriate amount in methanol, and its working stock solution
(250 ng/mL) was prepared by diluting the stock solution in
methanol.
Fig. 4. Typical multiple reaction monitoring mode chromatograms of human plasma spiked with (A) esomeprazole, (B) rabeprazole and (C) levosulpiride at LLOQ level (left
panel) and IS (right panel).
Table 1
Precision and accuracy data for back-calculated concentrations of calibration standards.
Concentration added (ng/mL) Esomeprazole (n¼5) Rabeprazole (n¼5) Levosulpiride (n¼5)
Mean (ng/mL) CV (%) Accuracy (%) Mean (ng/mL) CV (%) Accuracy (%) Mean (ng/mL) CV (%) Accuracy (%)
0.100 0.102 10.05 101.80 0.096 7.48 96.00 0.101 9.94 101.20
0.200 0.198 6.26 99.10 0.202 5.53 101.00 0.203 6.06 101.60
1.000 1.016 8.60 101.58 0.983 8.36 98.26 1.029 4.92 102.90
5.000 5.030 2.98 100.59 5.112 3.95 102.24 4.966 1.33 99.32
50.000 50.545 3.33 101.09 51.735 2.64 103.47 50.310 1.47 100.62
500.000 503.012 2.74 100.60 511.713 2.18 102.34 504.251 1.10 100.85
1000.000 1013.954 2.65 101.40 1000.592 3.25 100.06 1004.669 1.59 100.47
1600.000 1616.992 2.75 101.06 1571.033 5.16 98.19 1603.965 2.65 100.25
2000.000 2028.137 2.95 101.41 2078.221 3.31 103.91 2034.346 1.22 101.72
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A simple liquid–liquid extraction method was developed for
extraction of the analytes and IS from human plasma. Prior to
analysis, all frozen subject samples, calibration standards and QC
samples were thawed at ambient temperature. Then, 5 mL of ISworking stock solution was added into each 1.5 mL eppendorf tube
except for blank plasma. 50 mL of standards, QCs, subject samples
and blank plasma were transferred into eppendorf tubes. After
vortexing for 30 s, 50 mL of Milli-Q water was added to each tube
and vortexed to mix. The analytes and IS were extracted with 1 mL
of methyl tert-butyl ether:ethyl acetate (80:20, v/v) by vortexing
Table 2
Intra- and inter-day accuracy and precision of esomeprazole, rabeprazole and levosulpiride.
Analyte Level (ng/mL) Intra-day (n¼6) Inter-day (n¼30)
Mean (ng/mL) CV (%) Accuracy (%) Mean (ng/mL) CV (%) Accuracy (%)
Esomeprazole LLOQ (0.100) 0.100 9.96 99.83 0.101 9.57 100.93
LQC (1.000) 1.115 1.31 111.45 1.070 5.90 106.95
MQC (1000.000) 1029.001 7.10 102.90 1023.426 4.93 102.34
HQC (1600.000) 1623.924 2.59 101.50 1641.746 3.66 102.61
Rabeprazole LLOQ (0.100) 0.098 10.48 97.67 0.099 11.19 99.00
LQC (1.000) 0.992 7.78 99.15 1.012 7.69 101.19
MQC (1000.000) 976.600 8.03 97.66 999.933 5.68 99.99
HQC (1600.000) 1674.207 6.49 104.64 1667.869 4.80 104.24
Levosulpiride LLOQ (0.100) 0.096 8.91 95.67 0.098 9.87 98.40
LQC (1.000) 1.008 7.85 100.75 1.003 5.23 100.28
MQC (1000.000) 996.342 3.31 99.63 1008.885 3.59 100.89
HQC (1600.000) 1621.134 2.15 101.32 1622.351 2.42 101.40
Table 3







Recovery (%) Overall recovery
(Mean7CV, %)
Esomeprazole 1 486671.52 439972.42 90.39 91.6871.22
1000 4,564,89970.89 4,211,68371.50 92.26
1600 7,251,74870.44 6,699,12070.42 92.38
Rabeprazole 1 391671.29 357571.23 91.27 88.9672.36
1000 3,917,51671.07 3,415,01971.30 87.17
1600 6,242,95170.54 5,520,25370.36 88.42
Levosulpiride 1 911971.05 815770.75 89.45 89.8671.76
1000 9,131,23370.33 8,364,50570.84 91.60
1600 14,171,52270.89 12,543,58073.44 88.51
IS 250 2,190,80873.64 1,887,32371.06 86.15
Table 4
Stability data of esomeprazole, rabeprazole and levosulpiride in human plasma.
Condition Esomeprazole (n¼6) Rabeprazole (n¼6) Levosulpiride (n¼6)
Mean (ng/mL) CV (%) Change (%) Mean (ng/mL) CV (%) Change (%) Mean (ng/mL) CV (%) Change (%)
Bench top (27 °C, 8 h)
LQC 1.045 6.22 2.85 1.036 5.04 5.02 1.025 3.92 3.14
HQC 1706.695 3.67 0.97 1679.299 3.14 3.18 1645.523 4.85 1.37
Auto sampler (4 °C, 24 h)
LQC 1.039 8.59 2.25 1.039 8.56 5.36 1.024 4.15 3.00
HQC 1737.051 2.50 2.76 1682.042 4.39 3.35 1701.873 2.17 4.84
Dry extract (4 °C, 24 h)
LQC 1.052 8.25 3.54 1.052 8.25 6.69 1.003 6.58 0.97
HQC 1715.372 2.98 1.48 1650.543 5.31 1.41 1650.857 2.05 1.70
Freeze–thaw (80 °C, After 4 cycles)
LQC 1.061 6.08 4.45 1.061 6.08 7.62 1.008 5.68 1.39
HQC 1717.516 2.32 1.61 1715.603 3.61 5.41 1681.519 2.13 3.58
Long term (80 °C, 60 days)
LQC 1.021 6.85 1.96 1.009 9.98 3.05 1.017 7.41 4.47
HQC 1704.451 3.28 0.24 1694.291 2.53 1.83 1695.373 1.85 1.69
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The organic layer was transferred into a clean test tube and eva-
porated to dryness at 40 °C under a gentle stream of nitrogen in
the Turbo vap evaporator (Caliper life sciences, USA). The dried
extract was reconstituted with 0.2 mL of mobile phase and 2 mL of
aliquot was injected into the UPLC–MS/MS system for analysis.
2.5. Method validation
The bioanalytical method was thoroughly validated to meet theacceptance criteria of draft industrial guidance for the bioanaly-
tical method validation [26]. The method was validated for se-
lectivity, linearity, precision and accuracy, recovery, matrix effect,
dilution integrity and stability. The selectivity was evaluated by
comparing the chromatograms of six different blank human
plasma with corresponding spiked plasma at LLOQ QC level. Peak
areas of endogenous compounds co-eluting with the analytes
should be less than 20% of the peak area of LLOQ response, and
peak areas of endogenous compounds co-eluting with IS should be
less than 5% of the mean response of IS in LLOQ samples. Linearity
Fig. 5. Mean plasma concentration vs time proﬁles of (A) esomeprazole, (B) rabe-
prazole and levosulpiride (C).
Table 5
Pharmacokinetic data of esomeprazole, rabeprazole and levosulpiride (n¼6,
Mean7SD).





Tmax (h) 3.5070.55 3.3370.52 4.3370.52







Cmax, the maximum plasma concentration; Tmax, the time to reach Cmax; T1/2,
elimination half-life; AUC0–t, the area under the plasma concentration-time curve
from zero to the last sampling time; AUC0–α, the area under the plasma con-
centration-time curve from time zero to inﬁnity.
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2000 ng/mL. For the determination of linearity, ﬁve standard ca-
libration curves, containing at least nine non-zero standards, were
constructed by a weighted least squares (1/x2) linear regression
method through the measurement of the peak area ratio of analyte
to IS. In addition, blank and blankþ IS samples were analyzed to
conﬁrm the absence of direct interferences; blank and blankþ IS
data were not included to construct calibration curves. Intra-day
precision and accuracy were determined by analyzing six re-
plicates of each QC (LLOQ, LQC, MQC and HQC) sample of two
different batches on the same day. Inter-day precision and accu-
racy were determined by analyzing six replicates of each QC
(LLOQ, LQC, MQC and HQC) sample of ﬁve different batches. The
acceptance criteria included accuracy within715% deviation from
the nominal values, except for the LLOQ , where it should be720%and precision of715% coefﬁcient of variance (%CV), except for
LLOQ, where it should be720%. The extraction recovery of each
analyte was estimated at three different QC levels (six replicates of
each LQC, MQC and HQC) by comparing the peak area response of
extracted analytes with unextracted analytes (reconstitution so-
lution spiked with the analytes) that represent 100% recovery.
Similarly, recovery of IS was estimated by comparing the mean
peak area of extracted QC samples (n¼18) with mean peak area of
unextracted QC samples. Recovery of the analytes and IS should be
precise and reproducible at all QC levels. The matrix effect was
evaluated by comparing the peak areas obtained from each analyte
in post-extraction blank plasma samples with those of the re-
spective analyte dissolved at the same concentration in recon-
stitution solution (mobile phase). The matrix effect was de-
termined at MQC level using six replicates at each level for each
analyte, and IS was determined at a single concentration of
250 ng/mL. Dilution integrity was performed to extend the upper
concentration limits with acceptable precision and accuracy. Six
replicates of each analyte at concentration two times of the upper
concentration limit were prepared and diluted to 2- and 4-fold
with blank plasma. These samples were processed and analyzed.
Stability tests were conducted to evaluate the analyte stability in
stock solutions and plasma samples under different conditions.
The stock solution stability at room temperature and refrigerated
conditions (2–8 °C) was determined by comparing the area re-
sponse of the analytes (stability samples) with the response of the
sample prepared from fresh stock solution. Bench-top stability
(8 h), processed sample stability (autosampler stability for 24 h),
dry extract stability (8 h), freeze–thaw stability (four cycles) and
long-term stability (60 days) were tested at LQC and HQC levels
using six replicates at each level. Samples were considered to be
stable if assay values were within the acceptable limits of accuracy
(715%) and precision (715% CV).
2.6. Pharmacokinetic study
The pharmacokinetic study was carried out in healthy male
volunteers (n¼6). Blood samples were collected in K2-EDTA va-
cutainer collection tubes (BD, Franklin, NJ, USA) following oral
administration of esomeprazole (40 mg), rabeprazole (20 mg) and
levosulpiride (75 mg) at pre-dose and 0.25, 0.50, 1.00, 1.50, 2, 2.5,
3, 4, 5, 6, 8, 10, 12, 16 and 24 h. The tubes were centrifuged
(Thermo Scientiﬁc, Germany) at 3200 rpm for 10 min and then the
plasma was collected. The collected plasma samples were stored at
80 °C till use. This study was carried out as per the approval and
guidelines of the local ethical committee. Plasma samples were
spiked with the IS and processed as per the extraction procedure
described earlier. Along with the clinical samples, the QC samples
Fig. 6. Typical multiple reaction monitoring mode chromatograms of the analytes: (A) esomeprazole, (B) rabeprazole and (C) levosulpiride (left panel) in human volunteer
sample and IS (right panel).
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triplicate. Plasma concentration vs time proﬁles of esomeprazole,
rabeprazole and levosulpiride was analyzed by non-compart-
mental method using WinNonlin Version 5.3 (Pharsight Corpora-
tion, CA, USA).3. Results and discussion
3.1. Method development and optimization
3.1.1. Optimization of the mass spectrometric conditions
Mass spectrometric conditions were optimized so as to achieve
the maximum stable response of the precursor ions and the major
product ions of the analytes. Mass spectrometer was operated in
positive ion mode to get a good response. The inherent selectivity
of MRMmode for quantiﬁcation of the analytes was expected to bebeneﬁcial in developing a selective and sensitive method. All
analytes showed the singly charged protonated ions [MþH]þas
the prominent ion in the full scan of Q1 spectrum and was used as
the precursor ion to obtain Q3 product ion spectra. The cone
voltage and collision energy were optimized to get highest in-
tensity for precursor ion and product ion, respectively. The mass
transition ion pair was selected as m/z 346.1-198.1 for esome-
prazole, m/z 360.1-242.1 for rabeprazole and m/z 342.2-112.2
for levosulpiride. The product ion mass spectra for each analyte are
presented in Fig. 2.
3.1.2. Optimization of the chromatographic conditions
Chromatographic conditions, especially the composition of
mobile phase and column, were optimized in order to achieve a
good chromatographic resolution and symmetric analyte peak
shapes within a short run time. The feasibility of various mixtures
of solvents such as methanol and acetonitrile with different
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tered ﬂow rates on different types of columns such as C18 and C8
were tested for complete chromatographic resolution of the ana-
lytes and IS from interfering biological matrix. Finally, the gradient
mobile phase system consisting of 2 mM ammonium formate–
acetonitrile mixture (minutes, % mobile phase B): 0.01, 10; 0.20, 10;
0.50, 90; 0.70, 90; 0.80, 10; 1.00, 10, delivered with a 0.5 mL/min
ﬂow rate on a Hypersil gold C18 column achieved the good chro-
matographic separation of the analytes and IS with desired re-
sponse. The retention time of esomeprazole, rabeprazole, levo-
sulpiride and IS were 0.60, 0.54, 0.73 and 0.56 min, respectively.
Several compounds were investigated to ﬁnd a suitable IS and ﬁ-
nally, lansoprazole was found to be compatible with targeted
analytes in terms of extraction efﬁciency, chromatographic beha-
vior and ionization yield.
3.2. Method validation
3.2.1. Selectivity
Representative chromatograms obtained from blank plasma
sample and blank plasma spiked with LLOQ standard of each
analyte and IS are presented in Figs. 3 and 4. There were no sig-
niﬁcant endogenous interferences observed in the respective MRM
channel at the retention time of each analyte and IS in blank
plasma sample.
3.2.2. Linearity
Linearity of each calibration curve was determined by plotting
the peak area ratio of analyte to IS (y) versus the nominal con-
centration (x) of the calibration points, and ﬁtted to the y¼mxþc
using a regression factor (1/x2). The nine-point calibration curve
was found to be linear over the concentration range of 0.1–
2000 ng/mL for all the analytes. Correlation coefﬁcients were in
the range 0.980or2o0.995 for all the analytes. The accuracy va-
lues ranged from 96.00% to 103.91%, while the precision (%CV)
values ranged from 1.10 to 10.05 for all the analytes. Table 1
summarizes the calibration curve results for all the analytes.
3.2.3. Precision and accuracy
The intra- and inter-day precision and accuracy values
were within the acceptance limit for all the analytes and are
summarized in Table 2. The intra-day accuracy ranged between
95.67% and 111.45% with a precision of 1.31%–10.48%; the inter-day
accuracy between 98.40% and 106.95% with a precision of 2.42%–
11.19%.
3.2.4. Recovery
The extraction recoveries of all the analytes and IS were good
and reproducible. The mean overall recoveries (with the precision)
of all the analytes are summarized in Table 3.
3.2.5. Matrix effect
There was no effect of endogenous contribution from blank
plasma in the measurement of all the analytes and IS. The average
matrix factor values (matrix factor¼peak area of post-spiked
concentrations/peak area of neat concentrations) ranged from
0.897 to 0.996, while the precision (%CV) values ranged from 1.08%
to 2.36% for all the analytes.
3.2.6. Dilution integrity
The upper concentration limit was extended to 4000 ng/mL for
all the analytes by a half and quarter dilution with screened hu-
man blank plasma. The mean back-calculated concentrations for a
half and quarter dilution samples were within 85%–115% of nom-
inal value, while precision values ranged from 1.24% to 5.14% for all
the analytes.3.2.7. Stability studies
Analysis of stock solution stability was performed at the con-
centration of 2000 ng/mL. After storage for 24 days at 2–8 °C and
at room temperature for 6 h, more than 97% of esomeprazole, ra-
beprazole and levosulpiride remained unchanged. The results of
bench-top stability (8 h), processed sample stability (auto sampler
stability for 24 h), dry extract stability (8 h), freeze–thaw stability
(four cycles) and long-term stability (60 days) are summarized in
Table 4 and found to be within the acceptance limit.
3.3. Application of the method in pharmacokinetic study
The established UPLC–MS/MS method was successfully applied to
the determination of esomeprazole, rabeprazole and levosulpiride
concentrations in human plasma samples collected from healthy
volunteers (n¼6). The mean plasma concentrations vs time proﬁles
of esomeprazole, rabeprazole and levosulpiride are shown in Fig. 5.
In addition, the pharmacokinetic parameters are presented in Ta-
ble 5. The maximum concentration (Cmax) in human plasma
(1560.229 ng/mL for esomeprazole, 670.440 ng/mL for rabeprazole
and 171.689 ng/mL for levosulpiride) was attained at 3.50 h, 3.33 h
and 4.33 h (Tmax) for esomeprazole, rabeprazole and levosulpiride,
respectively. The area under curve from zero hour to last hour
measurable concentration (AUC0–t) and area under curve from zero
hour to inﬁnity (AUC0–α) for esomeprazole were 8181.486 ng h/mL
and 8191.343 ng h/mL, for rabeprazole 1749.192 ng h/mL and
1753.775 ng h/mL and for levosulpiride 1014.206 ng h/mL and
1015.472 ng h/mL. These values were in close proximity when com-
pared with earlier reported values [15–22]. Fig. 6 represents the
chromatograms of three analytes after oral administration.4. Conclusion
In summary, a selective, sensitive and rapid UPLC–MS/MS method
for simultaneous quantiﬁcation of esomeprazole, rabeprazole and
levosulpiride in human plasma was developed and fully validated as
per USFDA guidelines. Till date, there has been no reported UPLC–
MS/MS method for simultaneous quantiﬁcation of esomeprazole,
rabeprazole and levosulpiride in any biological matrix. This method
offers signiﬁcant advantages in terms of wide range of linearity, good
recovery, rapid extraction and short run time. Moreover, this method
provides superior sensitivity with the LLOQ as low as 0.1 ng/mL for
each analyte. Finally, the simplicity of sample preparation and the
short chromatographic runtime give the method capability for high
sample throughput. From the results of all the validation parameters,
we can conclude that the present method is useful for pharmacoki-
netic/bioequivalence studies with desired precision and accuracy.Acknowledgments
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